Pharmaceuticals

DEZHAN HEALTHCARE

DEZHAN HEALTHCARE released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 88.62 M, actual EPS CNY -0.0164

DEZHAN HEALTHCARE released FY2025 Annual Earnings on April 24 After-Market (BJT), actual revenue CNY 396.81 M, actual EPS CNY -0.1633

DEZHAN HEALTHCARE released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 119.31 M, actual EPS CNY -0.1351

DEZHAN HEALTHCARE FY2026 Q1 Earnings Release on April 30 After-Market BJT

DEZHAN HEALTHCARE FY2025 Annual Earnings Release on April 25, 2026 After-Market (BJT)

DEZHAN HEALTHCARE released FY2025 9 Months Earnings on October 24 After-Market (BJT), actual revenue CNY 277.5 M, actual EPS CNY -0.0287

DEZHAN HEALTHCARE released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 111.14 M, actual EPS CNY -0.0086

DEZHAN HEALTHCARE FY2025 Q3 Earnings Release on October 25, 2025, After-Market (BJT)

DEZHAN HEALTHCARE released FY2025 Semi-Annual earnings on August 22 After-Market (BJT), actual revenue CNY 166.36 M, actual EPS CNY -0.0201

DEZHAN HEALTHCARE released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 77.08 M, actual EPS CNY -0.0097

DEZHAN HEALTHCARE to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Dezhou Health Expected to Report Net Loss in H1 2025

Shanghai Yueye Reduces Its Shareholding in Deshenzheng

Dezheng Health's ESG Rating Dropped to CC

Shareholder Rights Change at Desheng Health, Chen Zhiwenlong Becomes a Major Shareholder

Desun Health Repurchases 43.1994 Million Shares

Dezhenshan Health Establishes Academy Expert Workstation with Yang Baofeng

Deshenzhan Health Announces Q1 2025 Earnings Report Showing Decrease in Net Profit

DEZHAN HEALTHCARE released FY2024 earnings on April 28 After-Market BJT, actual revenue CNY 466.49 M, actual EPS CNY -0.0095

DEZHAN HEALTHCARE released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 89.28 M, actual EPS CNY -0.0104

516120

159870

159133

516570

516220

159129

000813

Middle East geopolitical conflicts continue to escalate, with Iran and Saudi Arabia, two major petrochemical producing regions, being attacked on the same day, severely impacting global petrochemical supply. As a result, futures for chemical products such as ethylene glycol surged to their daily limit, and A-share chemical sectors experienced a strong rally, leading to a wave of daily limit surges. Coupled with price increases by global chemical companies and policy catalysts for domestic equipment upgrades, multiple factors are jointly boosting the sector's heat

Wallstreetcn

Fullgoal CSI Subdivision Chemical Industry Theme ETF

Penghua CSI Subdivision Chemical Industry Theme ETF

Tianhong CSI Chemicals Sub-industry ETF

E Fund CSI Petrochemical Industry ETF

Guotai CSI Subdivision Chemical Industry Theme ETF

Harvest CSI Chemicals Sub-industry ETF

Middle East Tensions Continue to Disrupt, Chemical Sector Sees Another Surge of Daily Limit Rises

688302

600513

09992

688136

Innovative drug concept stocks showed active performance, with JLPC touching the daily limit, Menovo hitting 5 daily limits in 6 days, and Kingchem, Hinova, SDKX, DEZHAN HEALTHCARE, and WBDE following suit. In morning trading, the military industry sector surged; Jianshe Industry hit 2 daily limits in 4 days, while North Long Dragon, GreatWall Military, Jieqiang Equipment, FIRMACO, and Guoke Group climbed

- On March 27, A-shares opened low but recovered slightly, with key indices reducing losses; various sectors like CRO and innovative pharmaceuticals showed strength, while memory and optical communication hardware adjusted.  
- The bond market saw a downturn, with government bond futures declining, and most domestic commodity futures also fell, particularly for indexes and certain metals.  
- Lithium battery material stocks remained strong, with significant production increases noted for energy storage cells, while innovative drug stocks and military sectors exhibited particular upward movements amidst geopolitical tensions affecting oil prices.

Hinova

JLPC

POP MART

Menovo

SDKX

WBDE

North Long Dragon

Guoke Group

Jieqiang Equipment

Kingchem

FIRMACO

GreatWall Military

Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%

细分化工

516020

On the first trading day of the Year of the Horse, the chemical sector surged, with multiple stocks in sub-sectors such as phosphorus chemicals and pesticides hitting the daily limit. Guotou Securities pointed out that after four years of a downward cycle, the industry is now at the threshold of a reversal, with capital expenditure experiencing negative growth for seven consecutive quarters, establishing a supply turning point. After the holiday, the market will shift from valuation repair to a price verification phase, with the supply and demand patterns of sub-varieties such as dyes, TMP, chemical fibers, and phosphorus chemicals optimizing, and prosperity is expected to continue

Hwabao WP CSI Subdivision Chemical Industry Theme ETF

The chemical sector's "good start" in the Year of the Horse marks the end of valuation repair, and the price increase realization period has arrived!

02279

Global markets faced volatility, with major indices declining due to geopolitical tensions. Investors are turning to penny stocks, which represent smaller companies with potential value. Notable penny stocks include Yonghe Medical Group, HG Metal Manufacturing, and Dezhan Healthcare, each with unique financial profiles and growth prospects. Yonghe Medical Group, focused on hair healthcare in China, shows strong cash flow despite being unprofitable. HG Metal Manufacturing, trading in steel products, demonstrates financial stability and growth. Dezhan Healthcare, specializing in cardiovascular drugs, remains pre-revenue but maintains strong liquidity. These stocks offer opportunities amidst market uncertainty.

Simplywall

YONGHE MEDICAL

HG Metal

Global Penny Stocks: 3 Hidden Gems With Market Caps Under US$2B

36Kr learned that DEZHAN HEALTHCARE stated on the interactive platform that the relevant experiments for the IND application of WYY injection for stroke indications have been basically completed, and the clinical trial application is expected to be submitted in the second half of the year

36Kr

DEZHAN HEALTHCARE: The relevant experiments for the IND application of WYY injection for stroke indications have been basically completed, and the clinical trial application is expected to be submitted in the second half of the year

603127

06127

002262

603590

688091

300363

Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

Zhitong

JOINN

NHWA

Konruns

SHANGHAI YIZHONG

Porton

Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

603229

603716

Innovative drug concept stocks collectively fell, Ausun Pharm hit the limit down, SDKX dropped over 10%, Thalys, DEZHAN HEALTHCARE, and Hinova had significant declines

Ausun Pharm

Thalys

Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

DEZHAN HEALTHCARE issued a notice of unusual movements. As of the date of this announcement, there is no need to correct or supplement the information previously disclosed by the company; as of the date of this announcement, the company has not discovered any undisclosed significant information that has a substantial impact on the trading price of the company's stock due to recent public media reports or market rumors; the company's production and operation situation is normal, and as of the date of this announcement, there have been no significant changes in the internal and external operating environment

DEZHAN HEALTHCARE: There has been no significant change in the internal and external operating environment

DEZHAN HEALTHCARE announced that it expects a net profit loss of 25 million to 50 million yuan in the first half of 2025, compared to a profit of 10.1526 million yuan in the same period last year, a year-on-year decline of 346.24%-592.48%

DEZHAN HEALTHCARE: Expected net loss of 25 million to 50 million yuan in the first half of the year

DEZHAN HEALTHCARE(000813.SZ)